Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS1 | P56192 | 8/20 | 0.38 |
| ▸ | CNR1 | P21554 | 10/20 | 0.37 |
| ▸ | CNR2 | P34972 | 10/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1337166 | 0.90 | ALPL (0.40) | CNR1CNR2ALPLEGFRALOX5 | |
| SCHEMBL1336848 | 0.87 | CNR1 (0.38) | CNR1CNR2EGFRALOX5ADORA3 | |
| SCHEMBL1339276 | 0.86 | MKNK1 (0.43) | CNR1CNR2EGFRALOX5ADORA3 | |
| SCHEMBL1338782 | 0.85 | CNR1 (0.37) | MARS1CNR1CNR2ALPLEGFR | |
| SCHEMBL3267367 | 0.83 | CDH1 (0.42) | CNR1CNR2 | |
| SCHEMBL1338161 | 0.82 | CNR1 (0.35) | CNR1CNR2ALPLEGFRALOX5 | |
| SCHEMBL1338074 | 0.82 | L3MBTL1 (0.40) | CNR1CNR2EGFRALOX5ADORA3 | |
| SCHEMBL1339414 | 0.81 | GABRG2 (0.43) | CNR1CNR2GABRA1 | |
| SCHEMBL1339434 | 0.79 | CNR1 (0.36) | CNR1CNR2ALPLOPRL1SIGMAR1 | |
| SCHEMBL1339573 | 0.79 | KDM4E (0.46) | CNR1CNR2GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063061-B2 | 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites | SANOFI-AVENTIS (FR) | 2011-11-22 | — | — | US | disclosed |
| EP-1940840-B1 | 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2010-07-21 | — | — | EP | disclosed |
| US-20080262020-A1 | 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| EP-1940840-A1 | 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007045758-A1 | 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262020-A1 | 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof | CYP11B2, CYP11B1, CYP2D6 | MARS1 2786/4885CNR1 262/4885CNR2 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.